Genetic Engineers apply precise techniques to modify the DNA of organisms, enabling advancements that impact medicine, agriculture, and environmental science. Through tools like CRISPR-Cas9, gene cloning, and recombinant DNA technology, they alter genetic material to enhance traits, correct mutations, or develop entirely new capabilities within cells. In healthcare, genetic engineers are at the forefront of developing gene therapies for inherited disorders, engineering immune cells to fight cancer, and advancing treatments for rare diseases. Their work also plays a critical role in the development of genetically modified organisms (GMOs), which can improve crop yield, resistance to pests, and tolerance to climate stress.
In industrial and research settings, genetic engineers collaborate with molecular biologists, biotechnologists, and data scientists to translate complex genetic insights into practical applications. Their innovations extend to synthetic biology, where they design new biological systems with potential in pharmaceuticals, biofuels, and biodegradable materials. Ethical and safety considerations are an integral part of their work, as they navigate the challenges of genome editing with responsibility and precision. By unlocking the ability to engineer life at the genetic level, they contribute to breakthroughs that have the potential to transform entire industries. Their expertise is reshaping our understanding of biology and redefining what is possible in science and technology. As the boundaries of genetic science expand, genetic engineers remain central to innovation that benefits both humanity and the planet.
Title : Prophylactic and molecular approaches for mitigating human influenza A viruses: i. Evaluating influenza vaccine effectiveness in the older population ii. Down-regulation of influenza virus genes with novel sirna-chimeric-ribozyme constructs
Madhu Khanna, University of Delhi, India
Title : Homology analysis of MPXV and VACV peptides underscores the need to consider both MPXV clades for vaccine development
Lara Isis Teodoro, Mayo Clinic, United States
Title : Development of a novel multi-component vaccine to address the burden of otitis media in high-risk populations
Ayesha Zahid, Griffith University, Australia
Title : High seroprevalence of RSV antibodies in adults indicates potential undetected transmission and requires further public health assessment
Lara Isis Teodoro, Mayo Clinic, United States
Title : The role of immunity in the pathogenesis of SARS-COV-2 and in the protection generated by COVID-19 in different age groups
Ahmed Abdulazeez, BHRUT Trust, United Kingdom
Title : New biomarkers in leishmania major vaccine development
Negar Seyed, Pasteur Institute of Iran, Iran (Islamic Republic of)
Title : Tubercular disease in children: Optimizing treatment strategies through disease insights
Elena Chiappini, University of Florence, Italy
Title : Approaches towards developing and establishing a biomanufacturing research & development, and manufacturing industry in Zimbabwe: A review of the need, potential funding sources, policy development and implementation
Elliot Nyagumbo, Midlands State University, Zimbabwe
Title : Racial disparities in pediatric pneumonia in Brazil: The role of structural racism forging inequalities in acess to vaccines
Livia Daflon Silva, Federal University of State of Rio de Janeiro, Brazil
Title : Capillary electrophoresis for adjuvanted multivalent recombinant vaccine purity determination
Ashley Prout, Merck, United States